Evan David Seigerman
Stock Analyst at BMO Capital
(3.38)
# 1,019
Out of 5,099 analysts
54
Total ratings
51.06%
Success rate
4.61%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Evan David Seigerman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| REGN Regeneron Pharmaceuticals | Maintains: Outperform | $725 → $850 | $692.58 | +22.73% | 9 | Dec 4, 2025 | |
| AMGN Amgen | Maintains: Outperform | $335 → $372 | $313.85 | +18.53% | 5 | Dec 3, 2025 | |
| NVO Novo Nordisk | Maintains: Market Perform | $50 → $46 | $46.36 | -0.78% | 8 | Nov 25, 2025 | |
| REPL Replimune Group | Upgrades: Market Perform | $2 → $11 | $10.30 | +6.80% | 5 | Nov 3, 2025 | |
| ABBV AbbVie | Maintains: Outperform | $215 → $240 | $222.99 | +7.63% | 8 | Sep 12, 2025 | |
| NGNE Neurogene | Maintains: Outperform | $22 → $26 | $19.74 | +31.71% | 2 | Jun 12, 2025 | |
| MRUS Merus | Maintains: Outperform | $96 → $110 | $96.36 | +14.16% | 1 | May 23, 2025 | |
| ACAD ACADIA Pharmaceuticals | Maintains: Outperform | $24 → $28 | $26.89 | +4.13% | 2 | May 19, 2025 | |
| ARVN Arvinas | Maintains: Outperform | $20 → $10 | $13.10 | -23.66% | 1 | May 5, 2025 | |
| MRK Merck & Co. | Maintains: Market Perform | $105 → $96 | $96.89 | -0.92% | 4 | Feb 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $70 → $112 | $91.68 | +22.16% | 1 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $83 → $100 | $66.74 | +49.84% | 2 | Jun 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $33 → $36 | $25.33 | +42.12% | 4 | May 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $9 → $3 | $5.66 | -47.00% | 1 | May 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $369 → $396 | $982.22 | -59.68% | 1 | Sep 6, 2022 |
Regeneron Pharmaceuticals
Dec 4, 2025
Maintains: Outperform
Price Target: $725 → $850
Current: $692.58
Upside: +22.73%
Amgen
Dec 3, 2025
Maintains: Outperform
Price Target: $335 → $372
Current: $313.85
Upside: +18.53%
Novo Nordisk
Nov 25, 2025
Maintains: Market Perform
Price Target: $50 → $46
Current: $46.36
Upside: -0.78%
Replimune Group
Nov 3, 2025
Upgrades: Market Perform
Price Target: $2 → $11
Current: $10.30
Upside: +6.80%
AbbVie
Sep 12, 2025
Maintains: Outperform
Price Target: $215 → $240
Current: $222.99
Upside: +7.63%
Neurogene
Jun 12, 2025
Maintains: Outperform
Price Target: $22 → $26
Current: $19.74
Upside: +31.71%
Merus
May 23, 2025
Maintains: Outperform
Price Target: $96 → $110
Current: $96.36
Upside: +14.16%
ACADIA Pharmaceuticals
May 19, 2025
Maintains: Outperform
Price Target: $24 → $28
Current: $26.89
Upside: +4.13%
Arvinas
May 5, 2025
Maintains: Outperform
Price Target: $20 → $10
Current: $13.10
Upside: -23.66%
Merck & Co.
Feb 5, 2025
Maintains: Market Perform
Price Target: $105 → $96
Current: $96.89
Upside: -0.92%
Nov 5, 2024
Maintains: Outperform
Price Target: $70 → $112
Current: $91.68
Upside: +22.16%
Jun 7, 2024
Maintains: Outperform
Price Target: $83 → $100
Current: $66.74
Upside: +49.84%
May 2, 2024
Reiterates: Outperform
Price Target: $33 → $36
Current: $25.33
Upside: +42.12%
May 15, 2023
Maintains: Outperform
Price Target: $9 → $3
Current: $5.66
Upside: -47.00%
Sep 6, 2022
Maintains: Outperform
Price Target: $369 → $396
Current: $982.22
Upside: -59.68%